Ebola treatment trial begins in Congo as citizens mourn hundreds

Researchers have initiated a trial of two experimental Ebola treatments in the Democratic Republic of Congo's Ituri province. The study began in early July at the Bunia’s Evangelical Medical Centre, the epicenter of the ongoing outbreak. This urgent research effort aims to combat the growing number of cases, with residents placing their hopes on these potential new treatments. The launch was characterized by a quiet urgency, with healthcare workers continuing their daily efforts to save lives amidst the arrival of ambulances and the demands of isolation wards.

In eastern Congo's Ituri province, a new clinical trial has begun to test two experimental Ebola treatments, remdesivir and MBP134, against the Bundibugyo virus, for which no specific treatments currently exist. This initiative offers hope to residents amidst a growing outbreak that has already infected over 1,400 people and caused 438 deaths. The World Health Organization announced the enrollment of the first participant, with survival rates to be tracked for 28 days. The trial, a collaboration involving Congolese and international health organizations, initially focuses on confirmed patients and may expand to include high-risk individuals in a later phase. Despite the urgency, researchers face challenges including community mistrust and insecurity, which have hampered previous response efforts.